23G transconjunctival sutureless vitrectomy safe & effective

Article

Twenty-three gauge transconjunctival sutureless vitrectomy is an effective surgical technique for the management of vitreoretinal diseases.

Twenty-three gauge transconjunctival sutureless vitrectomy is an effective surgical technique for the management of vitreoretinal diseases, according to a study published in the February issue of Retina.

Asheesh Tewari and colleagues from the Kresge Eye Institute, Wayne State University School of Medicine, Michigan, US conducted a retrospective chart review of 81 consecutive 23-gauge vitrectomy cases carried out by a single surgeon for various posterior segment conditions.

Mean follow-up was 6.5 months (range: three to nine months). Mean preoperative visual acuity (VA) was 20/150 and final VA was 20/70 (p<0.0001). Mean intraocular pressure (IOP) on the first day postoperatively was 14 mmHg (range: 6 - 28 mmHg). There was a single case of intraoperative retinal tear that required treatment with cryotherapy and 20 eyes of 48 phakic eyes (42%) had worsening cataracts during the postoperative period. There were no recorded cases of endophthalmitis or retinal detachment.

It was the conclusion of the researchers that 23-gauge transconjunctival sutureless vitrectomy is both safe and effective.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.